- Children who have had two to four wheezing episodes in the past year and have a family member with allergies or asthma.
- 24-47 months
- COMIRB number
Researchers at Children's Hospital Colorado want to learn more about the effectiveness of asthma medication in young children.
Participants will receive financial compensation for their time.
Purpose of the PARK study
This study hopes to find out if the asthma treatment medication Xolair™ (approved in children 6 years of age and older) helps prevent the development of asthma in young children as they grow older. The medication has been used in children older than 6 years of age, and our researchers want to know if it can be effective in younger children.
Research study details
Your child may qualify for this study if:
- They are between 24 months and 47 months of age
- They have had two to four wheezing episodes in the past year
- They have a family member with asthma or allergies
Study participants will be randomized into one of two study groups. This means they will be assigned a study group by chance. One group will take Xolair, and the other group will take a placebo (inactive fake medication). Research visits will take place at Children's Colorado on the Anschutz Medical Campus in Aurora, Colorado, and will include the following tests:
- Physical examination
- Breathing tests
- Allergy test
- Blood, nasal cell, urine/stool collection
All children in the study will be given standard medications and managed by the study doctor for the treatment of breathing symptoms, such as wheezing and cough during the study period.
PARK study duration
Your child's participation will last four years. The first two years include monthly visits when your child will receive Xolair or a placebo. The second two years are an observation period that includes clinic visits every four months and monthly telephone contacts.
If you are interested in this research study and would like to learn if your child is eligible to participate, please email us or call 720-777-0577.
Principal Investigator: Andrew Liu, MD